• Operating profit for the year increased by 165% in Danish kroner and in the fourth quarter with 1.130% compared to 2019/2020.

• Net Sales for the year increased by 51% in Danish kroner compared to 2019/2020. Net Sales in the fourth quarter increased by 682% in Danish kroner compared to the fourth quarter of 2020. Sales growth was driven by Cannasen® CBD Arthritis gel & Cannasen® CBD Psoriasis Gel reflecting market expansion in Sweden and the launch of CANNASEN® CBD Hairloss treatment in Denmark.

• In the year we have been granted subsiders of 1.930.241 DKK and in the quarter 1.103.247. We recently (October 2021) got our innobooster application approved, with 500.000 DKK granted and SMV pro with 150.000 DKK granted.

• Within R&D, CS MEDICA initiated phase 3 development according to the new regulation MDR, biocompatibility tests, absorption tests and clinical trials on all medical device products.

• Revenue expectation for the coming year is held at DKK 50 million, but with the majority in the latter half of the Year.

• July 30, 2021, CS MEDICA announced its intention to launch an IPO and list its shares on Spotlight Stock Market in Q3 2021. The offering included issue of units of DKK 22,3 million and an additional approx. DKK 10.8 million at a later stage if all warrants of series TO 1 are exercised. First day of trading was September 14th. The initial part of the IPO of units was subscribed to a total of approximately DKK 35.2 million, corresponding to a subscription ratio of approximately 158 percent.

• August 13, 2021, CS MEDICA announced that the Company has been approved for listing at Spotlight Stock Market.

• August 19, 2021, CS MEDICA announced good results in two tests performed at the Dermatology Clinic of the Medical University of Gdansk, an application test and a dermatological test on the Company's PSOR + ATOPIC Lotion.

• September 10, 2021, CS MEDICA announced clinical trial Phase III results from the intermediate report on NGA-01 (CANNASEN®CBD Arthritis Gel) against placebo. Analysis of the data indicates that CANNASEN®CBD Arthritis Gel (NGA-01) has an efficacy rate of 89 percent in reduction of pain in joints of participants with Osteoarthritis with joint pain in any of the joints; knee, hip, ankle, elbow, and shoulder.

• September 14, 2021, was the first day of trading in CS MEDICA's shares and warrants at Spotlight Stock Market.

• September 14, 2021, CS MEDICA announced that the Company has signed an agreement with Alsitan GmbH ("Alsitan") in Germany. The order, which concerns arthritis gel under a private label agreement, amounts to 40,000 units, corresponding to DKK 1.240.000 million in revenue. The order is expected to be delivered in September and December 2021.

• September 27, 2021, CS MEDICA announced that the Company will adjust its financial targets for the fiscal year 2020/2021. The previously communicated financial target of DKK 7 million will be adjusted to approx. DKK 3.6 million. The completion of the process of testing and getting approval by the ethics committee in India was prolonged due to Covid-19, in turn impacting and postponing the finalization of an agreement.

• October 5, 2021, CS MEDICA announced extended product availability together with Kronan Apotek in Sweden. In accordance with the purchase agreement, the products are entering the shelf of the 326 local pharmacies of Kronans Apotek as of October 4, 2021.

• November 5, 2021, CS MEDICA announced entering a reseller agreement for annasen®CBD product portfolio with DirectSalud in Spain.

Financial statements

4 Quarter (DKK) 2020/2021           2019/2020
Net sales   2.093.921                302.478
Gross profit     875.489                  53.366
Operating profit     263.779                  21.439
Depreciation and    - 602.191              - 190.869
amortisation
Net financials    - 52.549                - 62.575
Profit before   - 390.961              - 232.005
taxes
Net profit    364.763              - 254.798

Research and 1.564.342                745.032
development costs
Cash flow 10.130.177                574.662

Financial Ratios
Gross margin            42%                      18%
Operating margin           13%                       7%
Research and           75%                   246%
development i % of
sales
Net profit margin           17%                    -84%

Fiscal Year (DKK) 2020/2021               2018/2019
2019/2020
Net sales   3.179.557                  1.425.936
2.110.729
Gross profit   1.363.857                        825.643
682.654
Operating profit 1.191.406                        211.130
450.398
Depreciation and - 1.367.452         -              - 24.433
amortisation 384.516
Net financials   - 231.742         -            - 138.194
143.253
Profit before taxes   - 407.788                           48.503
- 77.371
Net profit     647.626                      - 119.076
- 54.579

Cash and cash                                4.169
equivalents 9.996.085 296.884
Research and   5.906.369                   1.043.151
development costs 1.732.137
cash flow                              86.195
9.699.201 691.217
Total Assets 27.411.166                   3.279.071
5.436.210
Equity 24.147.361                     - 1.759.061
  87.241

Financial Ratios
Gross margin                                          58%
  43%       32%
Operating margin                                         15%
  37%        34%
Research and                                           73%
development in % of 186%       82%
sales
Net profit margin                                           -8%
  20%       -3%
Equity ratio                                          54%
  88%        2%

Share performance
Basic earnings per      
share 0,05940
Total number of 10.902.000
shares, 30 Sept
Closing share price            
6,20

This disclosure contains information that CS MEDICA A/S is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528) and the Swedish Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact person, on 18-11-2021 20:08 CET.